Accreditation Information
The University of Texas Southwestern Medical Center is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation
The University of Texas Southwestern Medical Center designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Conflict of Interest
It is the University of Texas Southwestern Medical Center’s policy that participants in CME activities should be made aware of any affiliation or financial interest that may affect the faculty’s presentation. Each faculty member has completed and signed a conflict of interest statement. The faculty members’ relationships are disclosed in the course materials.

Discussion of Off-Label Use
Because this course is meant to educate physicians with what is currently in use and what may be available in the future, “off-label” drugs are discussed in the presentation. Authors have been requested to inform the audience when off-label use is being discussed and a statement has been included in the course materials.

Release Date: April 1, 2010
Expiration Date: April 1, 2011

Statement of Need
Chronic lymphocytic leukemia (CLL) is the most common form of leukemia found in adults in Western countries and is estimated to comprise over one-third of all new leukemia cases. It accounts for over 15,000 new diagnoses and over 4,000 deaths per year in the United States.

At the time of diagnosis, many patients do not necessarily need to be treated with chemotherapy until symptoms appear or unless there is evidence of rapid progression of disease. Standard treatments aim to control disease and symptoms rather than provide a cure.

In recent years, advances in the management of CLL have moved beyond traditional management with alkylating agents and purine analogs into regimens combining these two chemotherapy classes with monoclonal antibodies targeting CD20.

With these current developments, it is important for hematology/oncology practitioners to be able to better understand the clinical issues that guide proper staging, goal setting, and treatment planning. Practitioners need to be aware of new data, agents, and regimens within the context of day-to-day clinical practice.

References

Target Audience
The intended audience for the proposed ACCME program includes US-based hematology/oncology practitioners who practice in both the institutional and community setting and participate in the care of patients with CLL.

Learning Objectives
In compliance with ACCME guidance, action-oriented educational learning objectives have been developed to focus upon enhancing clinical outcomes specific to CLL patient needs.

To achieve these desired patient-related outcomes summarized above, hematology/oncology practitioners who manage CLL patients will:

• Accurately diagnose and classify CLL patients.
• Define treatment goals for this population.
• Discuss the results of recent studies of the use of various treatments for the treatment of CLL.
• Integrate recent treatment regimens and clinical data into treatment planning and selection.
• Incorporate current data with newer agents such as bendamustine into treatment administration to assure safety and effectiveness.
• Detail new developments in the management of adverse events related to the treatment and monitor patients to assure safety and that a full course of treatment can be given.
• Refer patients to appropriate investigative protocols as clinically appropriate.

How to Obtain CME Credit
To successfully complete this activity, the University of Texas Southwestern Medical Center requires that you read the learning objectives, read the monograph, and take the posttest on page 16. Please fill out the answer sheet portion in its entirety & submit to:

James Karger
UT Southwestern Medical Center
Fax: 214-648-2317
E-mail: James.Karger@UTSouthwestern.edu